Skip to main content
M
MANE
(NYSE)
Veradermics, Incorporated
$58.04-- (--)
Loading... - Market loading

Veradermics, Incorporated (MANE) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Veradermics, Incorporated
MANENYSEHealthcareBiotechnology

About Veradermics, Incorporated

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.

Company Information

CEOReid Waldman
Founded2019
IPO DateFebruary 4, 2026
Employees19
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSE (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone(228) 372-3376
Address
470 James Street, Suite 14 New Haven, Connecticut 06513 United States

Corporate Identifiers

CIK0001827635
CUSIP922967104
ISINUS9229671048
EIN84-3304423
SIC2834

Leadership Team & Key Executives

Reid Waldman, M.D.
Chief Executive Officer and Director
Tim Durso, M.D.
President
Dominic Carrano, CPA
Chief Financial Officer
Mark Neumann
Chief Commercial and Strategy Officer
Michael V. Greco, J.D.
General Counsel
John W. Childs
Director
Vlad Coric, M.D.
Director
Patrick Enright
Director
David Friedman, M.D.
Director
Jane Grant-Kels, M.D.
Director